Historical studies of radiation therapy and TMZ in newly diagnosed MGMT-methylated GBM have reported mOS ranging from 21.4 to 26.3 months, with confidence intervals spanning 17.4–34.7 months [46,47,48]. This evidence concerns the gene MGMT and glioblastoma.